Loading stock data…
ASTRAZENECA PLC ORD SHS $0.25 (AZN.L)
LSE11,970pGBX-144.00p (-1.19%)
Market ClosedLast close Aug 28
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AstraZeneca PLC in the Healthcare sector is trading at 11,970p with a market capitalization of $185.6B. Wall Street consensus targets 15,703p (22 analysts), implying a +31.2% move over the next 12 months. The stock is currently 24% below its 52-week high of 15,732p, remaining 12.9% below its 200-day moving average. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +31.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | $14.46B↓ | $15.19B↓ | $15.50B↑ | $15.29B↓ | $15.38B |
| Gross Profit | $11.98B↓ | $12.39B | $12.38B↓ | $12.61B↓ | $12.86B |
| Operating Income | $3.51B↓ | $3.58B↑ | $2.98B↓ | $4.25B↑ | $3.16B |
| Net Income | $2.45B↓ | $2.53B↑ | $2.33B↓ | $3.08B↑ | $2.51B |
Peer Comparison
JNJUNHPFE
Fundamentals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$185.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.33
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Strong income play. Yield provides a meaningful total return floor.
197.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.96%
Volume
Today's trading volume
3.57M
Recent News
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.
Alnylam stock drops on rival heart trial: Why analysts see core business safe
Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market value of RNA-therapeutics pioneer Alnylam Pharmaceuticals before the opening bell on Friday. Shares of Alnylam (NASDAQ: ALNY) fell nearly 4.9% in pre-market trading following the full presentation of data from a rival drug trial at the European Society of Cardiology Congress in Munich. The detailed results from AstraZeneca and Ionis Pharmaceu
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.
AstraZeneca (LSE:AZN) Reports Positive TEZSPIRE Phase 3 Results, Is The Discount Too Wide?
Amgen and AstraZeneca (LSE:AZN) reported positive top line Phase 3 results for TEZSPIRE in eosinophilic esophagitis, with clinically meaningful improvements through week 52. That kind of readout often prompts investors to revisit AstraZeneca stock. Even with a steady stream of late stage trial updates around TEZSPIRE, Tagrisso combinations and Enhertu, AstraZeneca’s share price has drifted, with a year to date share price return down 10.87% at £121.14. The 5 year total shareholder return of...